Experimental Nicotine Replacement Therapy (NRT) 2 mg + Experimental Nicotine Replacement Therapy (NRT) + Marketed Nicotine Lozenge + Marketed Nicotine Lozenge
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Tobacco Dependence
Conditions
Tobacco Dependence
Trial Timeline
Aug 1, 2009 → Jan 1, 2010
NCT ID
NCT01227720About Experimental Nicotine Replacement Therapy (NRT) 2 mg + Experimental Nicotine Replacement Therapy (NRT) + Marketed Nicotine Lozenge + Marketed Nicotine Lozenge
Experimental Nicotine Replacement Therapy (NRT) 2 mg + Experimental Nicotine Replacement Therapy (NRT) + Marketed Nicotine Lozenge + Marketed Nicotine Lozenge is a pre-clinical stage product being developed by Johnson & Johnson for Tobacco Dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT01227720. Target conditions include Tobacco Dependence.
What happened to similar drugs?
7 of 10 similar drugs in Tobacco Dependence were approved
Approved (7) Terminated (3) Active (2)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01227720 | Pre-clinical | Completed |
Competing Products
20 competing products in Tobacco Dependence